✦ LIBER ✦

The Gap between the Current Dyslipidemia Guidelines and the Physicians’ Treatment Targets in Patients with Type 2 Diabetes

✍ Scribed by Eren, Nihan Kahya; Harman, Ece; Dolek, Devrim; Emren, Sadık Volkan; Tütüncüoğlu, Aliye Pelin; Nazlı, Cem; Ergene, Oktay

Book ID: 122281391
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 141 KB
Volume: 62
Category: Article
ISSN: 1558-3597
DOI: 10.1016/j.jacc.2013.08.121

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The gap between guidelines and practice

The gap between guidelines and practice in the treatment of type 2 diabetes: A nationwide survey in Norway

✍ Trond G. Jenssen; Serena Tonstad; Tor Claudi; Kristian Midthjell; John Cooper 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 285 KB

The gap between guidelines and reality:

The gap between guidelines and reality: Type 2 diabetes in a national diabetes register 1996–2003

✍ B. Eliasson; J. Cederholm; P. Nilsson; S. Gudbjörnsdóttir; for the Steering Comm 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB

Control of diabetes and cardiovascular r

Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain

✍ D. Orozco-Beltrán; V. F. Gil-Guillen; F. Quirce; J. Navarro-Perez; M. Pineda; A 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB

Compliance with Clinical Practice Guidel

Compliance with Clinical Practice Guidelines for Type 2 Diabetes in Rural Patients: Treatment Gaps and Opportunities for Improvement

✍ Ellen L. Toth; Sumit R. Majumdar; Lisa M. Guirguis; Richard Z. Lewanczuk; Tzu K. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB

Pravastatin compared to bezafibrate in t

Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with Type 2 diabetes mellitus

✍ C. Rustemeijer; J. A. Schouten; H. J. Voerman; H. E. S. J. Hensgens; A. J. M. Do 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 2 views

Background Both HMG-CoA reductase inhibitors and ®bric acid derivates are used for the treatment of dyslipidemia in Type 2 diabetes patients. The aim of this study was to compare the lipid lowering effect of 40 mg pravastatin, a HMG-CoA reductase inhibitor, and 400 mg beza®brate, a ®bric acid deriva

Nateglinide – current and future role in

Nateglinide – current and future role in the treatment of patients with type 2 diabetes mellitus

✍ I. W. Campbell 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB